they have done for 30 years. The right thing . ">Current treatment methods include surgery, chemotherapy and radiotherapy .
Science Advances: DNA nanotubes break through the blood-brain barrier and bring hope to glioblastoma
Time of Update: 2022-01-08
the treatment effect and survival rate . >>DNA nanotechnology allows researchers to use synthetic DNA for various research purposes. The research team found that 10
MimiVac peptide mimic tumor vaccine received FDA approval for 2b clinical trial for the treatment of glioblastoma
Time of Update: 2021-12-06
November 19, 2021/eMedClub News/--Recently, a clinical stage biotechnology company MimiVac LLC announced , SurVaxM received the US Food and Drug Administration (FDA) approval notice in the 2b trial phase to evaluate the effectiveness of the newly diagnosed glioblastoma .
Clin Cancer Res: Oral Selinexor for the treatment of recurrent glioblastoma
Time of Update: 2021-12-03
For adult patients with recurrent glioblastoma, a single dose of 80 mg selinexor per week can induce remission, improve the patient's clinical relative progression-free survival rate, and controllable side effects .
Beihai Kangcheng's CAN008 injection for the treatment of glioblastoma (GBM) completed the first
Time of Update: 2021-11-15
Beihai Kangcheng has completed the Phase I clinical trial of CAN008 .
Neurology: Observational Study on the Effect of Levetiracetam Use Time on the Overall Survival Rate of Adult Isocitrate Dehydrogenase Wild-type Glioblastoma
Time of Update: 2021-11-12
mechanisms may affect seizure and tumor control at the same time . Studies have shown that several anti-epileptic drugs, mainly sodium valproate, levetiracetam and peracetam, have anti-tumor
Researchers publish new insights into how glioblastoma invades and grows
Time of Update: 2021-11-01
"Researchers have developed a method to generate syngeneic neural stem cells and use it as a comparator of patient-specific glioma starter cells to discover the pathogenesis-related mechanisms of glioblastoma and determine the patient’s risk Drug targets .
Antibody delivery technology enhances immunotherapy for glioblastoma and suppresses side effects
Time of Update: 2021-10-21
delivery and specific immune response, the modified antibody has achieved effective anti-tumor effects on preclinical GBM models. This is a challenge for ICIs in the clinical environment (the complete remission rate of the mouse in situ GBM
Nat Commun: "Fighting with poison", oncolytic virus enhances the anti-tumor innate immune response to glioblastoma
Time of Update: 2021-10-20
The results from a mouse tumor model with strong immunity further confirmed that macrophages, and to a lesser extent NK cells, mediate the anti-tumor cytotoxicity of the oncolytic herpes virus that produces antibodies .
Front Oncol: Fruquintinib + PD-1 inhibitor vs. Regorafenib + PD-1 inhibitor in the treatment
Time of Update: 2021-10-10
In a phase II clinical study, the objective response rate (ORR) of regorafenib combined with nivolumab in the treatment of refractory mCRC (MSS or pMMR) was 36%, and the median progression-free survival (PFS) was 7.
The Oncologist: Comparison of the efficacy of FTD/TPI and regorafenib in the treatment of patients with advanced colorectal cancer
Time of Update: 2021-10-10
001 oncologist>001-->The study included eligible patients from 2012 to 2017 and compared the real-world objective response rate (rwORR), the real-world disease control rate (rwDCR), and survival .
Applicable symptoms and effects of regorafenib
Time of Update: 2021-08-29
In our lives, medicines are divided into prescription medicines and over-the-counter medicines, and when buying these two, they must be purchased according
J Clin Oncol: Avapritinib vs. Regorafenib in the treatment of locally advanced unresectable
Time of Update: 2021-08-13
Therefore, the investigators carried out a phase III study of VOYAGER (NCT03465722) to evaluate the efficacy and safety of Avapritinib versus Regorafenib for third-line or above treatment of locally advanced unresectable or metastatic gastrointestinal stromal tumors .
with recurrent glioblastoma was accepted by the State Food and Drug Administration
Time of Update: 2021-07-06
announced today that after communicating with the National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab for the treatment of patients with recurrent glioblastoma (rGBM) has been accepted .